Structure of Entrectinib
CAS No.: 1108743-60-7
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Entrectinib (NMS-E628) is an orally active, BBB-penetrant inhibitor of TrkA/B/C, ROS1, and ALK, with IC50 values of 1, 3, 5, 12, and 7 nM, respectively. It induces apoptosis and cell cycle arrest in cancer cells, exhibits antitumor activity, and attenuates bleomycin-induced lung fibrosis in mice.
Synonyms: NMS-E628; RXDX-101
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 1108743-60-7 |
Formula : | C31H34F2N6O2 |
M.W : | 560.64 |
SMILES Code : | O=C(NC1=NNC2=C1C=C(CC3=CC(F)=CC(F)=C3)C=C2)C4=CC=C(N5CCN(C)CC5)C=C4NC6CCOCC6 |
Synonyms : |
NMS-E628; RXDX-101
|
MDL No. : | MFCD28129099 |
InChI Key : | HAYYBYPASCDWEQ-UHFFFAOYSA-N |
Pubchem ID : | 25141092 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H335 |
Precautionary Statements: | P261-P305+P351+P338 |
Target |
|
In Vitro:
Cell Line
|
Concentration | Treated Time | Description | References |
LLC-PK1 cells | 1 µM | 3.5 hours | To evaluate the interaction of Entrectinib with P-gp, results showed that Entrectinib had a lower AP-ER value (1.1-1.15), indicating a weaker interaction with P-gp. | PMC7283026 |
KM12 cells | <30 nM | 72 hours | To evaluate the inhibitory effect of gilteritinib on KM12 cells, the results showed that KM12 cells were highly sensitive to gilteritinib. | PMC7904790 |
Ba/F3 cells | 12.7 nM | 72 hours | To evaluate the inhibitory effect of gilteritinib on TPM3-NTRK1 G667C mutant Ba/F3 cells, the results showed that the mutant cells were more sensitive to gilteritinib. | PMC7904790 |
mouse primary bone marrow-derived macrophages (BMDMs) | 0.88 µM | 4 hours | inhibited MSU-induced IL-1β production | PMC10772347 |
human THP-1 cells | 2 µM | 1 hour | inhibited nigericin-induced IL-1β secretion and caspase-1 cleavage | PMC10772347 |
SY5Y-TrkB cells | 1 nM to 200 nM | 1 hour | Entrectinib significantly inhibited TrkB phosphorylation, with substantial inhibition observed at 1 nM concentration, and almost complete inhibition at 10 nM or higher concentrations. | PMC4792275 |
NLF-TrkB cells | 50 nM | 1 hour | Entrectinib almost completely inhibited TrkB phosphorylation in NLF-TrkB cells at 50 nM concentration. | PMC4792275 |
IMPE cells | 1 nM to 100 nM | 24 hours | To evaluate the effect of Entrectinib on BIM expression in IMPE cells, results showed increased BIM expression | PMC7478141 |
IMPE cells | 10 nM | 0 to 24 hours | To evaluate the effect of Entrectinib on BIM expression and RAF>MEK>ERK signaling in IMPE cells, results showed increased BIM expression and reactivation of RAF>MEK>ERK signaling | PMC7478141 |
IMPE cells | 10 nM to 1 μM | 24 hours | To evaluate the effect of BIM deletion on the sensitivity of IMPE cells to Entrectinib, results showed that BIM deletion reduced cell sensitivity to Entrectinib | PMC7478141 |
Ba/F3 cells | 50 nM | 72 hours | To evaluate the effect of Alectinib on ALK-TKI resistant mutations | PMC7904790 |
IMPE cells | 250 nM | 2 or 24 hours | To evaluate the effect of Cobimetinib on the RAF>MEK>ERK signaling pathway in IMPE cells, results showed that Cobimetinib alone effectively inhibited pERK at 2 h, but reactivation of pERK was detected at 24 h. | PMC7478141 |
MLE-12 cells | 250 nM | 2 or 24 hours | To evaluate the effect of Cobimetinib on the RAF>MEK>ERK signaling pathway in MLE-12 cells, results showed that Cobimetinib alone effectively inhibited pERK at 2 h, but reactivation of pERK was detected at 24 h. | PMC7478141 |
In Vivo:
Species
|
Animal Model
|
Administration | Dosage | Frequency | Description | References |
Rats | Brain distribution model | Intravenous injection | 100 mg/kg or 200 mg/kg | Once daily for 3 weeks followed by 1 week off | To evaluate the brain distribution of Entrectinib in rats, results showed that Entrectinib did not reach steady state within 6 hours, but its CSF/unbound plasma concentration ratio (CSF/Cu,p) was more favorable than that of crizotinib and larotrectinib. | PMC7283026 |
mice | BALB/c nu/nu mice | oral | 150 mg/kg | Single dose, lasting for 3 days | To evaluate the inhibitory effect of gilteritinib on KM12 cell xenografts, the results showed that gilteritinib significantly inhibited tumor growth. | PMC7904790 |
mice | LPS-induced systemic inflammation model | intraperitoneal injection | Single bolus followed by continuous infusion for 6 hours | significantly improved the survival rate of mice and inhibited the production of IL-1β in serum | PMC10772347 | |
nude mice | SY5Y-TrkB xenograft model | oral | 30 mg/kg | once daily for 5 days/week | Entrectinib significantly inhibited the growth of SY5Y-TrkB xenograft tumors and significantly prolonged event-free survival (EFS). | PMC4792275 |
Nude mice | HER2-positive breast cancer xenograft model | Oral | 10 mg/kg | single injection, lasted for 6 hours | The combination of Entrectinib and Pacritinib significantly suppressed tumor growth and induced apoptosis in HER2-positive breast cancer xenografts. | PMC11533721 |
mice | NOD-SCID mice | oral | 60 mg/kg | twice daily, 7 days/week | To evaluate the effect of Entrectinib on IMPE cell-derived tumors, results showed that BIM deletion reduced tumor sensitivity to Entrectinib | PMC7478141 |
mice | BALB/c nu/nu mice | oral | 15 mg/kg | twice per week | To evaluate the therapeutic effect of Alectinib on EML4-ALK I1171N +F1174I mutant tumors | PMC7904790 |
mice | BALB/c nu/nu mice | oral | 10 mg/kg | Once daily for 4 weeks | To evaluate the in vivo antitumor effect of Gilteritinib on EML4-ALK I1171N +F1174I mutant tumors, results showed that Gilteritinib significantly reduced tumor volume. | PMC7904790 |
mice | NOD-SCID mice | oral | 0.5 mg/g | Every 12 hours for 48 hours | To evaluate the effect of Cobimetinib in combination with Entrectinib on IMPE cell-derived tumors, results showed that the combination significantly delayed the onset of drug resistance. | PMC7478141 |
Female severe combined immunodeficient beige mice (BALB/cAjcl-nu/nu) | KM12-ER xenograft model | Oral | 15 mg/kg | Once daily for 14 days | Evaluate the inhibitory effect of simvastatin combined with entrectinib on resistant tumor growth | PMC11194613 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT05770544 | Solid Tumor|Haematological Mal... More >>ignancy|Malignancy|Malignant Neoplasm|Lymphoproliferative Disorders|Neoplasms by Histologic Type|Neoplasms by Site|Cancer|Brain Neoplasms|Melanoma|Glioma Less << | PHASE2|PHASE3 | RECRUITING | 2025-10-29 | Belfast City Hospital, Belfast... More >>, BT9 7AB, United Kingdom|University Hospital Birmingham, Birmingham, B15 2TT, United Kingdom|Birmingham Children's Hospital, Birmingham, United Kingdom|Bristol Royal Hospital for Children, Bristol, BS2 8BJ, United Kingdom|Bristol Haematology and Oncology Centre, Bristol, BS2 8ED, United Kingdom|Addenbrooke's Hospital, Cambridge, CB2 OQQ, United Kingdom|Velindre Cancer Centre, Cardiff, CF14 2TL, United Kingdom|Western General Hospital, Edinburgh, EH4 2XU, United Kingdom|The Beatson Hospital, Glasgow, G12 OYN, United Kingdom|Royal Hospital for Children Glasgow, Glasgow, G51 4TF, United Kingdom|Leeds General Infirmary, Leeds, LS1 3EX, United Kingdom|Leicester Royal Infirmary, Leicester, LE1 5WW, United Kingdom|Alder Hey Hospital, Liverpool, L14 5AB, United Kingdom|The Royal Marsden Hospital, London Borough of Sutton, SM2 5PT, United Kingdom|University College London Hospital, London, NW1 2BU, United Kingdom|Guy's Hospital, London, SE1 9RT, United Kingdom|Great Ormond Street Hospital, London, WC1N 3JH, United Kingdom|Royal Manchester Children's Hospital, Manchester, M13 9WL, United Kingdom|The Christie Hospital, Manchester, M20 4BX, United Kingdom|Great North Children's Hospital, Newcastle, NE1 4LP, United Kingdom|Freeman Hospital, Newcastle, NE7 7DN, United Kingdom|Churchill Hospital, Oxford, OX3 7LE, United Kingdom|John Radcliffe Hospital, Oxford, OX3 9DU, United Kingdom|Weston Park Hospital, Sheffield, S10 2SJ, United Kingdom|Southampton General Hospital, Southampton, SO16 6YD, United Kingdom|Clatterbridge Cancer Centre, Wirral, CH63 4JY, United Kingdom Less << |
NCT03066661 | Cancers With NTRK, ROS1, or AL... More >>K Gene Fusions Less << | NO_LONGER_AVAILABLE | - | 1-844-Startrk (782-7875), San ... More >>Diego, California, 92121, United States Less << | |
NCT02650401 | Solid Tumors|CNS Tumors | PHASE1|PHASE2 | ACTIVE_NOT_RECRUITING | 2025-06-15 | Rady Childrens Hospital, San D... More >>iego, California, 92123, United States|UCSF Benioff Children's Hospital, San Francisco, California, 94158, United States|Children's Hospital Colorado, Aurora, Colorado, 80045, United States|Egleston Children's Hospital at Emory University Atlanta, Atlanta, Georgia, 30322, United States|University of Chicago, Chicago, Illinois, 60637, United States|Johns Hopkins University, Baltimore, Maryland, 21205, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Washington University,St. Louis Children's Hospital, Saint Louis, Missouri, 63110, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Nationwide Children's Hospital, Columbus, Ohio, 43205, United States|Oregon Health & Science Uni, Portland, Oregon, 97239, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States|St. Jude Children'S Research Hospital, Memphis, Tennessee, 38105, United States|Texas Children's Cancer and Hematology Center, Houston, Texas, 77030, United States|Primary Children's Hospital, Salt Lake City, Utah, 84113, United States|The Hospital for Sick Children, Toronto, Ontario, M5G 1X8, Canada|Beijing Children's Hospital, Capital Medical University, Beijing, DUMMY_VALUE, China|Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China|Centre Leon Berard, Lyon, 69373, France|H?pital de la Timone, Oncologie Pédiatrique, Marseille, 13385, France|Universitaetsklinikum Heidelberg, Heidelberg, Baden Wuerttemberg, 69120, Germany|Hong Kong Children's Hospital, Hong Kong, 00000, Hong Kong|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, 20133, Italy|Hospital Infantil Universitario Nino Jesus, Madrid, 28009, Spain|Royal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP, United Kingdom|Royal Marsden NHS Foundation Trust, Sutton, SM2 5PT, United Kingdom Less << |
NCT06694129 | Non-Small Cell Lung Cancer|ROS... More >>1 Gene Rearrangement|Resistance|Targeted Therapy Less << | NOT_YET_RECRUITING | 2027-12-01 | - | |
NCT02568267 | Breast Cancer|Cholangiocarcino... More >>ma|Colorectal Cancer|Head and Neck Neoplasms|Lymphoma, Large-Cell, Anaplastic|Melanoma|Neuroendocrine Tumors|Non-Small Cell Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Papillary Thyroid Cancer|Primary Brain Tumors|Renal Cell Carcinoma|Sarcomas|Salivary Gland Cancers|Adult Solid Tumor Less << | PHASE2 | ACTIVE_NOT_RECRUITING | 2025-12-31 | Dignity Health St Joseph's Hos... More >>pital and Medical Center, Phoenix, Arizona, 85013, United States|Mayo Clinic, Phoenix, Arizona, 85054, United States|City of Hope Cancer Center, Duarte, California, 91010, United States|Scripps Clinic, La Jolla, California, 92037, United States|University of California San Diego Moores Cancer Center, La Jolla, California, 92093, United States|Southern California Kaiser Permanente, Los Angeles, California, 90027, United States|University of Southern California Medical Center, Los Angeles, California, 90032, United States|Univ Of California Irvine College Of Medicine, Orange, California, 92868, United States|UCSF Mount Zion Medical Ctr, San Francisco, California, 94115, United States|Sarcoma Oncology Center, Santa Monica, California, 90403, United States|University of Colorado Cancer Center, Aurora, Colorado, 80045, United States|Yale University, New Haven, Connecticut, 6519, United States|Georgetown University Medical Center Lombardi Cancer Center, Washington, District of Columbia, 20007, United States|Florida Cancer Specialists - Sarasota, Sarasota, Florida, 34232, United States|H. Lee Moffitt Cancer Center and Research Inst., Tampa, Florida, 33612-9497, United States|University Cancer & Blood Center, LLC, Athens, Georgia, 30607, United States|Winship Cancer Institute, Atlanta, Georgia, 30322, United States|Southeastern Regional Medical Center, Inc., Newnan, Georgia, 30265, United States|Northwestern University, Chicago, Illinois, 60611, United States|Advocate Medical Group - Park Ridge, Luther Lane - Oncology, Park Ridge, Illinois, 60068, United States|Midwestern Regional Medical Center, Zion, Illinois, 60099, United States|Weinberg Cancer Institution at Franklin Square, Baltimore, Maryland, 21237, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, 48109, United States|Karmanos Cancer Center, Detroit, Michigan, 48201, United States|Henry Ford Hospital, Detroit, Michigan, 48202, United States|Regents of the University of Minnesota, Minneapolis, Minnesota, 55455, United States|Washington University, Saint Louis, Missouri, 63128, United States|Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley, Las Vegas, Nevada, 89169, United States|North Shore Hem Onc Associates, East Setauket, New York, 11733, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10022, United States|Levine Cancer Institute, Charlotte, North Carolina, 28204, United States|Duke Cancer Institute, Durham, North Carolina, 27710, United States|OSU, James Cancer Hospital, Columbus, Ohio, 43210, United States|Cancer Treatment Centers of America, Tulsa, Oklahoma, 74133, United States|Oregon Health & Science Univ, Portland, Oregon, 97239, United States|Mary Crowley Medical Research Center, Dallas, Texas, 75230, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|Baylor Scott & White Health, Temple, Texas, 76508, United States|University of Utah Hospitals & Clinics, Salt Lake City, Utah, 84112, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, 22031, United States|Virginia Oncology Associates - Hampton, Norfolk, Virginia, 23502, United States|University of Washington Seattle Cancer Care Alliance, Seattle, Washington, 98109, United States|Liverpool Hospital, Liverpool, New South Wales, 2170, Australia|Newcastle Private Hospital, Newcastle, New South Wales, 2305, Australia|Flinders Medical Centre, Bedford Park, South Australia, 5042, Australia|Austin Health, Heidelberg, Victoria, 3084, Australia|Antwerp University Hospital, Edegem, 2650, Belgium|Beijing Cancer Hospital, Beijing, 100142, China|Sichuan Provincial Cancer Hospital, Chengdu, 610041, China|Cancer Center of Guangzhou Medical University, Guangzhou, 510000, China|Zhejiang Cancer Hospital, Hangzhou, 310022, China|Harbin Medical University Cancer Hospital, Harbin, 150081, China|Shanghai chest hospital, Shanghai, 200030, China|Fudan University Shanghai Cancer Center, Shanghai, 200120, China|Shenzhen People's Hospital, Shenzhen, 510852, China|Tianjin Cancer Hospital, Tianjin, 300060, China|Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan City, 430023, China|Institut de Cancerologie de l Ouest, Angers, 49055, France|Institut Bergonie, Bordeaux, 33076, France|Centre Leon Berard, Lyon, 69373, France|H?pital Nord - AP-HM Marseille#, Marseille cedex 20, 13915, France|H?pital de la Timone, Marseille cedex 5, 13385, France|Institut de Recherche en Cancérologie de Montpellier, Montpellier, 34090, France|Institut Curie, Paris, 75005, France|Institut De Cancerologie De L'ouest - Rene Gauducheau - Biology, Saint Herblain, 44805, France|Institut Claudius Regaud, Toulouse, 31059, France|Institut Gustave Roussy, Villejuif cedex, 94805, France|Evang. Lungenklinik Berlin Klinik für Pneumologie, Berlin, 13125, Germany|Universitaetsklinikum Carl Gustav Carus TU Dresden, Dresden, 01307, Germany|Universitaetsmedizin Goettingen, G?ttingen, 37075, Germany|NCT Uniklinikum Heidelberg, Heidelberg, 69120, Germany|Universitaetsklinikum Koeln, K?ln, 50937, Germany|Princess Margaret Hospital, Hong Kong, Hong Kong|The University of Hong Kong, Hong Kong, Hong Kong|Queen Elizabeth Hospital, Kowloon, DUMMY_VALUE, Hong Kong|The Chinese University of Hong Kong, Shatin, 123456, Hong Kong|Seconda Università degli Studi di Napoli, Napoli, Campania, 80131, Italy|Università Campus Bio-Medico di Roma, Roma, Lazio, 128, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, 20133, Italy|Azienda Socio Sanitaria Territoriale Niguarda (Ospedale Niguarda Ca' Granda), Milano, Lombardia, 20162, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, Toscana, 56126, Italy|Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia, Perugia, Umbria, 6132, Italy|IOV - Istituto Oncologico Veneto - IRCCS, Padova, Veneto, 35128, Italy|Aichi Cancer Center Hospital, Aichi, 464-8681, Japan|National Cancer Center Hospital, Chuo, 104-0045, Japan|NHO Kyushu Cancer Center, Fukuoka, 811-1395, Japan|Hyogo Cancer Center, Dept of Respiratory Medicine, Hyogo, 673-8558, Japan|National Cancer Center Hospital, Kashiwa-shi, 277-8577, Japan|NHO Shikoku Cancer Center, Matsuyama-shi, 791-0280, Japan|Miyagi Cancer Center, Miyagi, 981-1293, Japan|Niigata Cancer Center Hospital, Niigata, 951-8566, Japan|Osaka City General Hospital, Osaka, 534-0021, Japan|Kindai University Hospital, Osaka, 589-8511, Japan|Shizuoka Cancer Center, Shizuoka, 411-8777, Japan|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Asan Medical Center., Seoul, 05505, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, 120-752, Korea, Republic of|NKI The Netherlands Cancer Institute, Amsterdam, 1066 CX, Netherlands|Leids Universitair Medisch Centrum, Leiden, 2333 ZA, Netherlands|Uniwersyteckie Centrum Kliniczne, Gdansk, 80-214, Poland|Centrum Onkologii-Instytut im.M.Sklodowskiej Curie, Gliwice, 44-101, Poland|Szpital Kliniczny Przemienienia Panskiego Uni. Medycznego im. Karola Marcinkowskiego, Pozna?, 60-569, Poland|Centrum Onkologii Instytut im. M. Sklodowskiej-Curie, Klinika Nowotworow Ukladu Chlonnego, Warszawa, 02-781, Poland|National University Hospital, Singapore, 119228, Singapore|National Cancer Centre, Singapore, 169610, Singapore|Centro Nacional de Investigaciones Oncológicas(CNIO), Fuenlabrada, Madrid, 28942, Spain|Vall d?Hebron Institute of Oncology (VHIO), Barcelona, Barcelona, 08035, Spain|Hospital Universitario Ramon y Cajal, Madrid, 28034, Spain|Hospital Universitario Clínico San Carlos, Madrid, 28040, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital Universitario La Paz, Madrid, 28046, Spain|Hospital Clinico Universitario Virgen de la Victoria, Malaga, 29010, Spain|Hospital Universitario Virgen del Rocio, Sevilla, 41013, Spain|National Cheng Kung University Hospital, Tainan, 70457, Taiwan|National Taiwan University Hospital, Taipei, 00100, Taiwan|Taipei Veterans General Hospital, Taipei, 11217, Taiwan|Addenbrookes Hospital, Cambridge, CB2 0QQ, United Kingdom|Sarah Cannon Research Institute, London, W1G 6AD, United Kingdom|The Christie, Manchester, M20 4BX, United Kingdom Less << |
NCT02097810 | Locally Advanced Solid Tumors|... More >>Metastatic Solid Tumors Less << | PHASE1 | COMPLETED | 2020-06-02 | UC Irvine Medical Center, Oran... More >>ge, California, 92868, United States|University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, California, 94158, United States|University Of Colorado, Aurora, Colorado, 80045, United States|Georgetown University Medical Center, Washington, District of Columbia, 20007, United States|Florida Cancer Specialists - Sarasota, Sarasota, Florida, 34232, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Tennessee Oncology, Nashville, Tennessee, 37203, United States|University of Texas M.D. Anderson Cancer Center, Houston, Texas, 77030, United States|Samsung Medical Center, Seoul, 06531, Korea, Republic of Less << |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
1.78mL 0.36mL 0.18mL |
8.92mL 1.78mL 0.89mL |
17.84mL 3.57mL 1.78mL |
Tags: Entrectinib | NMS-E628 | RXDX-101 | RXDX101 | RXDX 101 | RXDX-101 | ROS Kinase | Trk Receptor | Anaplastic lymphoma kinase (ALK) | Autophagy | Tropomyosin related kinase receptor | Anaplastic lymphoma kinase | ALK tyrosine kinase receptor | CD246 | Cluster of differentiation 246 | KM12 cells | cancer | lung fibrosis | tumor | fibroblasts cells | 1108743-60-7
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL